Looking for bonds that will hold their own in a period of rising interest rates? I think I��e found a good hiding place in Osterweis Strategic Income (OSTIX).
See Also: 24 Stocks for 2014
In my view, the 30-year bull market in bonds��hich saw yields on ten-year Treasuries fall from a high of 15.8% in September 1981 to a low of 1.4% in July 2012��s history. Rates are likely to rise, albeit gradually and with some interruptions, for years to come. Because prices of most fixed-income investments move in the opposite direction of yields, bond investors are sailing into the wind.
What to do? The obvious move is to invest in short-term bond funds. Their bonds come to term quickly so, when rates are rising, investors can frequently reinvest proceeds from maturing bonds in higher-yielding IOUs. The problem is that high-quality short-term bond funds pay virtually zilch. For instance, Vanguard Short-Term Corporate Bond Index ETF (VCSH), an exchange-traded fund, yields all of 1.4%.
Best Communications Equipment Stocks To Watch Right Now: Two Harbors Investment Corp (TWO)
Two Harbors Investment Corp. (Two Harbors), incorporated on May 21, 2009, operates as a real estate investment trust (REIT). The Company is focused on investing in, financing and managing residential mortgage-backed securities (RMBS), residential mortgage loans, residential real properties, and other financial assets. The Company focuses on security selection and implements a relative value investment approach across various sectors within the residential mortgage market. Its target assets include Agency RMBS, Non-Agency RMBS, residential mortgage loans, residential real properties and other financial assets comprising approximately 5% to 10% of the portfolio. The Company has designated certain of its subsidiaries as taxable REIT subsidiaries (TRSs). Capitol Acquisition Corp. (Capitol) is a wholly owned indirect subsidiary of Two Harbors. The Company is externally managed and advised by PRCM Advisers LLC, a wholly owned subsidiary of Pine River Capital Management L.P. (Pine River).
The Company invests primarily in mortgage pass-through certificates, collateralized mortgage obligations and other residential mortgage-backed securities representing interests in or obligations backed by pools of mortgage loans issued by Federal National Mortgage Association (Fannie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Government National Mortgage Association (GNMA) (collectively GSEs). The Company also invests in residential mortgage-backed securities that are not issued by the GSEs (non-Agency RMBS) and United States Treasuries. At December 31, 2011, the Company had total assets of approximately $8.1 billion, of which $6.2 billion, or 77.1%, represented its RMBS portfolio. At December 31, 2011, $5.1 billion, or 80.9%, of its RMBS portfolio was comprised of Agency RMBS, $0.9 billion, or 14.9%, of its RMBS portfolio was comprised of senior non-Agency RMBS, and the remaining $0.2 billion, or 4.2%, was comprised of other non-Agency RMBS. The remaining $1.9 billion of assets consisted p! rimarily of United States Treasuries classified as trading instruments, cash, restricted cash, mortgage loans held-for-sale, receivables, derivative assets and prepaid assets.
Advisors' Opinion:- [By David Hanson]
This week at the Barclays Capital Global Financials Conference, droves of CEOs, CFOs, and CIOs trotted on stage to address a room full of eager analysts. One of the lone mREITs represented was Two Harbors (NYSE: TWO ) . CEO Tom Siering and CIO Bill Roth weighed in on the current environment.�
- [By Amanda Alix]
That was a big loss, and the stock price immediately began to tumble. Approximately two hours before markets closed on Thursday, CYS had lost 4.33%. Not only that, but it was dragging fellows Annaly (NYSE: NLY ) , American Capital Agency (NASDAQ: AGNC ) , Armour Residential (NYSE: ARR ) , and hybrid Two Harbors (NYSE: TWO ) down, as well. Interestingly, Western Asset stayed green, despite its downgrade one day earlier.
Top 5 Quality Companies To Buy For 2014: Intrexon Corp (XON)
Intrexon Corporation, incorporated on April 19, 2004, is engaged in the business of synthetic biology. Using the Company�� suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery.
The Company�� LEAP technology facilitates the automated identification of an individual cell with the highest levels of expression, quality and potency from a population of over 100,000 cells. Its mAbLogix platform complements UltraVector with a library of human antibodies that exceeds 500 million. By immortalizing human tonsils, which consists of lymphatic tissue containing B-cells, its mAbLogix platform creates a B-cell library that can generate antibodies against an almost infinite number of new antigens.
The UltraVector gene design and fabrication platform
The Company�� gene program design platform, which it refer to as UltraVector, is an integrated suite of tools comprising advanced DNA construction technology and components, cellular and protein engineering tools, computational models and statistical methods which facilitate the rapid design, build and testing of complex systems. The UltraVector platform allows the Company to translate gene programs into standard components that can be designed, manufactured and tested in an automated format. This technology enables it to engineer at the cellular level from biological sources.
UltraVector DNA design is computer-automated and ! utilizes a set of defined construction rules to assemble components that are stored in its DNA library. In addition to the number of gene components in its UltraVector library, it is designing and creating enzymatic and regulatory components that provide control over genome integration and gene regulation. Its RheoSwitch Therapeutic System is a three-component transcriptional regulator that provides inducible gene expression. The RheoSwitch Therapeutic System provides the ability to not only express proteins/enzymes of interest, but also the ability to control the level and timing of expression to achieve a biological outcome. Other ongoing programs include its Attsite recombinases, which mediate predictable gene exchange into host cells thereby eliminating many of the difficulties seen with traditional gene insertion.
Cell Systems Informatics
The Company�� Cell systems informatics permits design, as well as testing and learning about new gene targets or product pathways. Its bioinformatics software and database systems for mapping cellular pathways when combined with its genome-scale modeling and experimental data, including, gene expression profiling and protein engineering, enable the Company to optimize selection and development of gene programs and cellular systems for its collaborators. Its computational modeling and simulation platform enables the development of predictive computer models of organisms, from microbes to humans. This platform builds virtual cells from their basic molecular components, and can simulate the activity of the cell�� complete reaction network.
The Company is designing proteins with post-translational modifications. It is also working to develop enzyme inhibitors and fusion proteins for a variety of applications in human and animal therapeutics. Its protein engineering may utilize one or more of its technologies to obtain catalysis activitiesits component library, the generation of component variants sequence, evolutionary analy! sis and s! tructure-based sequence alignment, computer-aided drug discovery, de novo, or synthesized or generated, and comparative protein modeling, molecular dynamics simulation and free energy analysis, antibody design and humanization, antigenicity prediction, protein pharmacokinetics optimization, and/or in silico support of enzyme engineeringand quantitative structure-function relationships with machine learning algorithms to optimize, facilitate and prioritize protein variant libraries for the advancement of its collaborators.
LEAP-cell identification and selection
The Company�� Laser-Enabled Analysis and Processing technology (LEAP), is an instrument that merges semiconductor manufacturing technologies for cell processing applications to provide high levels of control and scale to cell purification and stem cell culture management. The LEAP platform can identify and purify cells of interest from large libraries of cells created by its UltraVector and bioinformatics technologies using a laser-based purification process, thereby providing a mechanism of testing the degree of protein expression in genetically modified cells, as well as means to learn from the genetic building process.
mAbLogix- antibody discovery
The Company�� mAbLogix antibody discovery platform, or mAbLogix platform, enables production of B-cell libraries for discovery of antibodies. The mAbLogix platform permits antigen targeting using fully human monoclonal and polyclonal antibodies. Its mAbLogix antibody discovery process consists of two major activities: the build of human B-cell libraries expressing a large number of antibodies, and the testing of these libraries based on an analysis of B-cells that express antibodies in response to a chosen antigen.
The Company competes with AbD SeroTec, Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Societe Des Systemes Biologiques, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc.,! AIIM The! rapeutics and Open Monoclonal Technology, Inc.
Advisors' Opinion:- [By Ben Levisohn]
Overvalued companies include MWI Veterinary (MWIV) and�Stericycle (SRCL), while companies with attractive valuations include Cardinal Health (CAH), Selected Medical (SEM). He’s not a fan of Intrexon (XON) but calls�Aratana (PETX) a “hidden gem.”
- [By Jon C. Ogg]
Intrexon Corp. (NYSE: XON) was started as Buy at Mizuho Securities, started as Equal Weight at Barclays and started as Overweight at J.P. Morgan.
Nokia Corp. (NYSE: NOK) was raised to Hold from Sell at Deutsche Bank, raised to Neutral from Underperform at Credit Suisse and
Canaccord Genuity raised its price target to $5.50 from $3.30. - [By John Udovich]
Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Top 5 Quality Companies To Buy For 2014: Pebblebrook Hotel Trust(PEB)
Pebblebrook Hotel Trust, through Pebblebrook Hotel, L.P., operates as a real estate investment trust. The company acquires and invests primarily in hotel properties located in the United States. It holds interests in the Doubletree Bethesda Hotel and Executive Meeting Center located in Bethesda, Maryland; Sir Francis Drake Hotel located in San Francisco, California; and InterContinental Buckhead Hotel located in Atlanta, Georgia. As a REIT, the company is not subject to federal income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. The company was founded in 2009 and is based in Bethesda, Maryland.
Advisors' Opinion:- [By Jonas Elmerraji]
First up is Pebblebrook Hotel Trust (PEB), the $2.2 billion hotel owner with 14 hotels under its umbrella. The firm started off the year rallying hard, climbing more than 14% from the start of January to early March. Since then, shares have been slugging sideways. But the sideways moves are laying the framework for a second rally leg in PEB this May. Here's how to trade it:
Pebblebrook is currently forming an ascending triangle pattern, a bullish setup that's formed by a horizontal resistance level above shares at $35, and uptrending support to the downside. Basically, as PEB bounces in between those two technical price levels, it's getting squeezed closer to a breakout above that $35 price ceiling. When that breakout happens, we've got a buy signal.
Momentum adds some confidence to the staying power in PEB's eventual breakout -- 14-day RSI has been making higher lows since early February, well before the triangle pattern started forming in Pebblebrook's price. That said, it's crucial to wait for this stock to catch a bid above $35 before putting cash in the trade.
- [By Jonas Elmerraji]
Small-cap hotel investment REIT Pebblebrook Hotel Trust (PEB) is setting up a similar pattern to the one in EXR -- with a few exceptions.
PEB isn't forming an ascending triangle; support isn't in the same sort of uptrend in this stock. Instead, PEB is forming a rounding pattern with resistance at $28. Rounding patterns look just like they sound -- they indicate a shift in control from sellers to buyers. While this setup is most common as a "bottoming" pattern, PEB's price action doesn't change the implications if shares can break out above $28. That's our buy signal.
Whenever you're looking at any technical price pattern, it's critical to think in terms of buyers and sellers. Triangles, rectangles and other price pattern names are a good quick way to explain what's going on in this stock, but they're not the reason it's tradable. Instead, it all comes down to supply and demand for shares.
That resistance line at $28 is a price where there's an excess of supply of shares; in other words, it's a place where sellers have been more eager to take recent gains and sell their shares than buyers have been to buy. That's what makes the move above it so significant -- a breakout indicates that buyers are finally strong enough to absorb all of the excess supply above that price level. Wait for that signal to happen before you jump into this stock.
- [By Marc Bastow]
Hotel properties real estate investment trust Pebblebrook Hotel Trust (PEB) raised its quarterly dividend 44% to 23 cents per share, payable April 15 to shareholders of record as of March 31.
PEB Dividend Yield: 2.58%
Top 5 Quality Companies To Buy For 2014: E.I. du Pont de Nemours and Company(DD)
E. I. du Pont de Nemours and Company operates as a science and technology company worldwide. It operates in seven segments: Agriculture & Nutrition, Electronics & Communications, Performance Chemicals, Performance Coatings, Performance Materials, Safety & Protection, and Pharmaceuticals. The Agriculture & Nutrition segment provides hybrid seed corn and soybean seed, herbicides, fungicides, insecticides, value enhanced grains, and soy protein under the Pioneer brand name. The Electronics & Communications segment supplies materials and systems for photovoltaic products, consumer electronics, displays, and advanced printing. The Performance Chemicals segment offers fluorochemicals, fluoropolymers, specialty and industrial chemicals, and white pigments for various markets, such as plastics and coatings, textiles, mining, pulp and paper, water treatment, and healthcare. The Performance Coatings segment supplies high performance liquid and powder coatings for motor vehicle origi nal equipment manufacturers (OEM); the motor vehicle after-market; and general industrial applications, such as such as coatings for heavy equipment, pipes and appliances, and electrical insulation. The Performance Materials segment provides polymers, elastomers, films, parts, and systems and solutions for the automotive OEM and associated after-market industries, as well as electrical, electronics, packaging, construction, oil, photovoltaics, aerospace, chemical processing, and consumer durable goods. The Safety & Protection segment primarily offers nonwovens, aramids, and solid surfaces for the construction, transportation, communications, industrial chemicals, oil and gas, electric utilities, automotive, manufacturing, defense, homeland security, and safety consulting industries. The Pharmaceuticals segment represents its interest in the collaboration relating to Cozaar/Hyzaar antihypertensive drugs. The company was founded in 1802 and is headquartered in Wilmington, Dela ware.
Advisors' Opinion:- [By Rich Duprey]
All told, Monsanto,�DuPont� (NYSE: DD ) ,�and�Syngenta� (NYSE: SYT ) control 53% of the world's seed production, yet their control of our food supply is almost all-encompassing, because they�cross-license�their technology between themselves and with other companies.
- [By John Divine]
Chemical giant E.I. du Pont de Nemours (NYSE: DD ) lost 2.2% today as a Bank of America analyst downgraded the stock from buy to neutral. Here, DuPont is somewhat a victim of its own success: With the stock's solid performance thus far this year, there aren't many visible catalysts on the horizon justifying that continued trend. The downgrade even said broad economic growth would be needed to justify a buy rating, which, according to the IMF, seems pretty unlikely.
- [By John Divine]
Chemical giant E.I. du Pont de Nemours (NYSE: DD ) was one of the 26 Dow decliners today, losing 2%. Even though the stock offers an impressive 3.4% dividend, Wall Street wasn't swayed by that large income distribution today. DuPont and Monsanto are currently the two biggest players in genetically modified seeds, the controversial technique that has come to dominate agriculture in recent years. Ninety-three percent of soybeans, for example, were planted with genetic modifications this year.�
- [By Matt Thalman]
Before we hit the Dow losers, let's look at the index's big winner of the week: DuPont (NYSE: DD ) , which ended the week higher by 7.54% after gaining 4.13% on Tuesday alone. The big move came as the result of DuPont's Q1 results, in which it matched expectations on revenue, beat estimates on earnings per share, and raised its dividend by 5%. The company also reaffirmed its 2013 full-year forecast, which is 2% to 7% higher than what DuPont posted in 2012. �
No comments:
Post a Comment